When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002 and raised its 1st funding round within a year of its incorporation.

Where is Amicus Therapeutics located?

Amicus Therapeutics is headquartered in Philadelphia, United States.

How many employees does Amicus Therapeutics have?

As of May 31, 2026, the latest employee count at Amicus Therapeutics is 619.

Is Amicus Therapeutics a funded company?

Amicus Therapeutics is a funded company, having raised a total of $91M across 13 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 2002.

How much is Amicus Therapeutics worth?

The last known valuation of Amicus Therapeutics was $***** as of Dec 20, 2025.

When was the latest funding round of Amicus Therapeutics?

Amicus Therapeutics' latest funding was a $***** Post IPO round on Oct 02, 2023, with participation from 1 investor.

What is the annual revenue of Amicus Therapeutics?

Annual revenue of Amicus Therapeutics is between $500M and $1B as on Dec 31, 2025

Where does Amicus Therapeutics rank among its competitors?

Amicus Therapeutics ranks 29th amongst 280 active competitors, of which 77 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Amicus Therapeutics?

Amicus Therapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Amicus Therapeutics - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapies for rare and orphan diseases. It has a pipeline of small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases. These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. Its drug pipeline includes migalastat, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, and SD-101 for the treatment of the rare genetic connective tissue disorder Epidermolysis Bullosa (EB).

Website: amicusrx.com
Social
Email ID: *****@amicusrx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2002

Location

Philadelphia, United States

Stage

Acquired

Total Funding

$91M in 13 rounds

Latest Funding Round

Post IPO, Oct 02, 2023, $*****

Last Known Valuation

$***** as on Dec 20, 2025

Investors

Quaker Partners Management & 11 more

Ranked

29^th among 280 active competitors

Annual Revenue

$500M - $1B as on Dec 31, 2025

Employee Count

619 as on May 31, 2026

Investment & Acquisitions

Scioderm & 1 more

Similar Companies

BridgeBio & 314 more

Exit Details

Acquired by BioMarin Pharmaceutical (Dec 19, 2025)

View Amicus Therapeutics' full profile

Amicus Therapeutics is associated with 9 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AMICUS THERAPEUTICS, INC CIN: 20-0422823 , United States, Active	Jan 01, 2002	-	517 (As on Dec 31, 2023)	-
Amica Pharma s.r.o. CIN: 06326315 , Czech Republic, Active	Aug 07, 2017	-	-
Amicus Therapeutics Europe Limited CIN: 0773.536.990 , Belgium, Active	Sep 05, 2021	-	-	-
Amicus CIN: 40008151627 , Latvia, Active	Dec 23, 2009	-	3 (As on Dec 31, 2012)	-
AMICUS PRODUKT d.o.o. CIN: 51727762734 , Croatia, Active	Mar 15, 2020	€0 - €1M (As on Dec 31, 2024)	-
AMICIUS d.o.o. CIN: 83707055404 , Croatia, Active	Feb 27, 2022	€0 - €1M (As on Dec 31, 2024)	-
AMICUS group d.o.o CIN: 92683092449 , Croatia, Active	Feb 19, 2017	€0 - €1M (As on Dec 31, 2024)	-
AMICUS THERAPEUTICS INC CIN: 1178879 , United States, Active	Feb 03, 2002	$500M - $1B (As on Dec 31, 2025)	-	-
Amicus Therapeutics, Inc. CIN: 710869350 , United States, Active	Feb 03, 2002	$500M - $1B (As on Dec 31, 2025)	260 (As on Dec 31, 2024)	-

Amicus Therapeutics got acquired by BioMarin Pharmaceutical on Dec 19, 2025.

Click here to take a look at Amicus Therapeutics's acquisition in detail

Amicus Therapeutics has raised a total funding of $91M over 13 rounds. Its first funding round was on Jul 2002. Its latest funding round was a Post IPO round on Oct 02, 2023 for $*****. 1 investor participated in its latest round. Amicus Therapeutics has 12 institutional investors.

Here is the list of recent funding rounds of Amicus Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 02, 2023	7009968	Post IPO	8822025	9749573	9834931	5293910
Feb 16, 2018	3706928	Post IPO	4568606	3133279	3589188	3127130
Apr 28, 2017	3094734	Post IPO	5684203	1544950	7165191	HBM Healthcare Investments

Access funding benchmarks and valuations. Sign up today!

View details of Amicus Therapeutics's funding rounds and investors

Amicus Therapeutics' employee count trend

Amicus Therapeutics has 619 employees as of May 26. Here is Amicus Therapeutics's employee count trend over the years:

Employee count trend for Amicus Therapeutics

Uncover Amicus Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Amicus Therapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Amicus Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
29th	Amicus Therapeutics 2002, Philadelphia (United States), Acquired	Developer of therapies for rare and orphan diseases	$91M	Avoro Capital, Frazier Life Sciences & 10 others	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Amicus Therapeutics's competitors? Click here to see the top ones

Amicus Therapeutics has acquired 2 companies including Scioderm and Callidus Biopharma. Amicus Therapeutics has not made any investments as of now.

Here is the latest report on Amicus Therapeutics's sector:

Free

Rare Diseases - Sector Report

Edition: August, 2026 (65 Pages)

View all reports related to Amicus Therapeutics

Media has covered Amicus Therapeutics for a total of 30 events in the last 1 year, 13 of them have been about company updates and 1 about partnerships.